Phase III Trials Begin for Boehringer's Hepatitis C Drug

[Guest guest]

Phase III Trials Begin for Boehringer's Hepatitis C Drug

Enrolling 1,875 patients with chronic genotype-1 Hepatitis C, Boehringer will begin three phase III trials for BI 201335, an oral protease inhibitor.

Boehringer begins late-stage hep C trial

4/27/11

Boehringer Ingelheim has begun enrolling patients in North America for a phase III trial of its chronic hepatitis C virus (HCV) candidate, which already has fast track designation from US regulators.

BI 201335 is an oral protease inhibitor and will be tested with standard-of-care in both treatment-naive and treatment -experienced patients with chronic genotype-1 HCV.

Continue reading this entire article:http://www.inpharm.com/news/155103/boehringer-bi-201335-hepatitis-c-trial

http://www.hepatitis-central.com/mt/archives/2011/05/phase_iii_trial.html